Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG. Moreau P, et al. Among authors: leleu x. Lancet Oncol. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7. Lancet Oncol. 2021. PMID: 33662288 Review.
Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy.
Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Geneviève F, Zandecki M, Laï JL, Leleu X, Jouet JP, Bauters F, Harousseau JL, Bataille R, Mary JY; Intergroupe Francophone du Myélome. Facon T, et al. Among authors: leleu x. Blood. 2001 Mar 15;97(6):1566-71. doi: 10.1182/blood.v97.6.1566. Blood. 2001. PMID: 11238092 Free article.
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, Hulin C, Benboubker L, Fuzibet JG, Renaud M, Moreau P, Avet-Loiseau H. Harousseau JL, et al. Among authors: leleu x. Haematologica. 2006 Nov;91(11):1498-505. Epub 2006 Oct 17. Haematologica. 2006. PMID: 17043025 Clinical Trial.
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM. Francis LK, et al. Among authors: leleu x. Clin Cancer Res. 2006 Nov 15;12(22):6826-35. doi: 10.1158/1078-0432.CCR-06-1331. Clin Cancer Res. 2006. PMID: 17121904
Emerging drugs in multiple myeloma.
Ghobrial IM, Leleu X, Hatjiharissi E, Hideshima T, Mitsiades C, Schlossman R, Anderson KC, Richardson P. Ghobrial IM, et al. Among authors: leleu x. Expert Opin Emerg Drugs. 2007 Mar;12(1):155-63. doi: 10.1517/14728214.12.1.155. Expert Opin Emerg Drugs. 2007. PMID: 17355220 Review.
382 results